HLUYY - H. Lundbeck A/S

Other OTC - Other OTC Delayed Price. Currency in USD
40.56
+0.37 (+0.92%)
At close: 11:29AM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close40.19
Open41.22
Bid0.00 x 0
Ask0.00 x 0
Day's Range40.56 - 41.22
52 Week Range38.65 - 73.90
Volume868
Avg. Volume3,525
Market Cap8.068B
Beta (3Y Monthly)0.35
PE Ratio (TTM)13.54
EPS (TTM)2.99
Earnings DateN/A
Forward Dividend & Yield1.80 (4.23%)
Ex-Dividend Date2019-03-27
1y Target EstN/A
  • What Do Analysts Think About H. Lundbeck A/S's (CPH:LUN) Earnings Trend?
    Simply Wall St.17 days ago

    What Do Analysts Think About H. Lundbeck A/S's (CPH:LUN) Earnings Trend?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Heed Analysts' Advice on Lundbeck: Sit Tight
    GuruFocus.com19 days ago

    Heed Analysts' Advice on Lundbeck: Sit Tight

    Danish pharmaceutical company H. Lundbeck A/S (OCSE:LUN) is searching for ways to renew investor optimism. Warning! GuruFocus has detected 4 Warning Signs with ABBV. Over the past several years, Lundbeck has aggressively cut costs and made a few small licensing deals to boost profitability.

  • Did You Miss H. Lundbeck's (CPH:LUN) 87% Share Price Gain?
    Simply Wall St.last month

    Did You Miss H. Lundbeck's (CPH:LUN) 87% Share Price Gain?

    When we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make significant gains if you buy good quality businesses at the right price. To wit, the H. Lundbeck share...

  • Reuters2 months ago

    Drugmakers Jazz, Alexion, Lundbeck to pay $123 million to resolve U.S. charity kickback probe

    Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones. The U.S. Justice Department on Thursday said Jazz Pharmaceuticals Plc, Lundbeck and Alexion Pharmaceuticals Inc were the latest companies to settle claims stemming from an industry-wide probe of drugmakers' financial support of patient assistance charities. The government in an earlier settlement said drugmakers used such charities as a means to improperly pay the copay obligations of Medicare patients using their drugs, in violation of the Anti-Kickback Statute.

  • Reuters2 months ago

    Drugmakers Jazz, Alexion, Lundbeck to pay $123 mln to resolve U.S. charity kickback probe

    Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones. The U.S. Justice Department on Thursday said Jazz Pharmaceuticals Plc, Lundbeck and Alexion Pharmaceuticals Inc were the latest companies to settle claims stemming from an industry-wide probe of drugmakers' financial support of patient assistance charities. The government in an earlier settlement said drugmakers used such charities as a means to improperly pay the copay obligations of Medicare patients using their drugs, in violation of the Anti-Kickback Statute.

  • Business Wire2 months ago

    Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development

    Group Aims to Bring Disease-Associated Biomarker Through FDA’s Drug Development Tools Qualification Program

  • What Are Analysts Saying About H. Lundbeck A/S’s (CPH:LUN) Earnings Trend?
    Simply Wall St.3 months ago

    What Are Analysts Saying About H. Lundbeck A/S’s (CPH:LUN) Earnings Trend?

    H. Lundbeck A/S's (CPH:LUN) most recent earnings announcement in December 2018 indicated that the business benefited from a strong tailwind, leading to a double-digit earnings growth of 49%. Below, I'veRead More...

  • Can H. Lundbeck A/S (CPH:LUN) Maintain Its Strong Returns?
    Simply Wall St.3 months ago

    Can H. Lundbeck A/S (CPH:LUN) Maintain Its Strong Returns?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Many investors are still learning about theRead More...

  • Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer
    Zacks4 months ago

    Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer

    Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.

  • Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat
    Zacks4 months ago

    Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat

    Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.

  • Lilly (LLY) Hits 52-Week High, Can the Run Continue?
    Zacks4 months ago

    Lilly (LLY) Hits 52-Week High, Can the Run Continue?

    Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids
    Zacks4 months ago

    Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids

    Sanofi's (SNY) influenza vaccine, Fluzone Quadrivalent (0.5mL dose), gains an FDA nod for treating children in six to 35-month age group.

  • AbbVie's Imbruvica Fails in Phase III Pancreatic Cancer Study
    Zacks4 months ago

    AbbVie's Imbruvica Fails in Phase III Pancreatic Cancer Study

    AbbVie's (ABBV) Imbruvica falls short of meeting the primary endpoint of PFS or OS benefit in a phase III study that probed its combo usage in first-line metastatic pancreatic cancer.

  • Lilly Stops Lartruvo Promotion as Confirmatory Study Fails
    Zacks4 months ago

    Lilly Stops Lartruvo Promotion as Confirmatory Study Fails

    Eli Lilly's (LLY) Lartruvo combo is unable to demonstrate the clinical benefit for the primary endpoint of OS rate in a phase III study related to treating patients with metastatic soft tissue sarcoma.

  • Will H. Lundbeck A/S’s (CPH:LUN) Earnings Grow In The Year Ahead?
    Simply Wall St.4 months ago

    Will H. Lundbeck A/S’s (CPH:LUN) Earnings Grow In The Year Ahead?

    Looking at H. Lundbeck A/S's (CPH:LUN) earnings update in September 2018, analyst consensus outlook seem bearish, as a -9.0% fall in profits is expected in the upcoming year against the Read More...

  • Do You Know What H Lundbeck A/S’s (CPH:LUN) P/E Ratio Means?
    Simply Wall St.6 months ago

    Do You Know What H Lundbeck A/S’s (CPH:LUN) P/E Ratio Means?

    This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it practical, we’ll show how H Lundbeck A/S’s (CPH:LUN) Read More...

  • Simply Wall St.7 months ago

    What Kind Of Shareholder Owns Most H Lundbeck A/S (CPH:LUN) Stock?

    If you want to know who really controls H Lundbeck A/S (CPH:LUN), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more Read More...